Strategic partnerships are an important part of our business strategy to create value for investors and patients.
Catalyst and ISU Abxis, a leading Korean biopharmaceutical company (086890.KQ-KOSDAQ), formed a strategic collaboration in 2013 to advance the development and commercialization of Catalyst's next-generation Factor IX development candidate, CB 2679d/ISU304 for the prevention and treatment of bleeding in individuals with hemophilia B. The collaboration is focused on advancing CB 2679d/ISU304 through IND-enabling preclinical development and Phase 1/2 clinical development in individuals with hemophilia B. Preclinical development has been completed and ISU commenced the Phase 1/2 clinical trial in June 2017.
Catalyst is entitled to up front and milestone payments and has retained worldwide commercialization rights, except for ISU Abxis’ right of first refusal for commercialization rights in Korea, and subject to a future profit sharing arrangement.
Catalyst and Mosaic Biosciences, Inc., a leader in protein engineering and protein-therapeutic delivery with ophthalmology expertise, formed a strategic collaboration in 2017 to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry AMD and other serious inflammatory retinal diseases. The collaboration will improve the pharmacokinetic (PK) properties of Catalyst’s lead anti-C3 proteases, with a goal of delivering product candidates that have a target profile of at least once quarterly intravitreal (IVT) dosing in humans and better potency compared with competitors with monthly or bi-monthly dosing.
Eric Furfine, Ph.D., who led preclinical development for Regeneron’s Eylea™ and was Chief Scientific Officer for Eleven Biotherapeutics’ ocular protein programs, is leading Mosaic’s ophthalmology efforts.
Catalyst and Mosaic will co-fund the research; Catalyst will retain global commercial rights for all collaboration products and Mosaic will receive product sublicense fees and/or milestone payments and royalties.